SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
0 |
N/A |
N/A |
N/A |
2024-08-13 |
2024-06 |
0 |
-0.13 |
N/A |
N/A |
2024-05-14 |
2024-03 |
0 |
-0.21 |
N/A |
N/A |
2024-03-28 |
2023-12 |
0 |
-0.25 |
N/A |
N/A |
2023-11-09 |
2023-09 |
0 |
-0.33 |
N/A |
N/A |
2023-08-10 |
2023-06 |
0 |
-0.31 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-06 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2022-11-14 |
Alliance Global Partners |
Upgrade |
|
Buy |
2022-06-27 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2021-07-20 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2019-11-14 |
Maxim Group |
Upgrade |
Hold |
Buy |
2019-04-07 |
Alliance Global Partners |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-21 |
BURNS JOHN THOMAS |
Chief Financial Officer |
101.93K |
Stock Award(Grant) |
2024-01-21 |
FRANCOMANO ROBERT |
Officer |
40.92K |
Stock Award(Grant) |
2024-01-21 |
KALIN KATHERINE BACH |
Director |
8.50K |
Stock Award(Grant) |
2017-12-28 |
LOPEZ FABIO |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Stock Award(Grant) |
2024-01-21 |
SCHEINBERG DAVID A |
Director |
10.58K |
Stock Award(Grant) |
2024-01-21 |
STERGIOU ANGELOS M |
Chief Executive Officer |
376.42K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Alyeska Investment Group, L.p. |
1.25M |
1.96M |
4.41% |
2023-06-29 |
Vanguard Group Inc |
946.71K |
1.49M |
3.34% |
2023-06-29 |
Blackrock Inc. |
283.37K |
444.89K |
1.00% |
2023-06-29 |
Geode Capital Management, LLC |
188.07K |
295.26K |
0.66% |
2023-06-29 |
Equitable Holdings, Inc. |
135.00K |
211.95K |
0.48% |
2023-06-29 |
State Street Corporation |
97.13K |
152.49K |
0.34% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
592.27K |
929.87K |
2.09% |
2023-06-29 |
Vanguard Extended Market Index Fund |
318.24K |
499.64K |
1.12% |
2023-05-30 |
Fidelity Extended Market Index Fund |
101.70K |
174.42K |
0.36% |
2023-08-30 |
iShares Micro Cap ETF |
63.00K |
92.61K |
0.22% |
2023-05-30 |
Fidelity Total Market Index Fund |
36.80K |
63.11K |
0.13% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
25.07K |
43.00K |
0.09% |
Dividend |
Date |
0.42 |
2010-12-09 |
0.15 |
2010-09-09 |
Split |
Date |
1 : 50 |
2019-11-08 |
1 : 50 |
2019-11-06 |
1 : 30 |
2018-01-02 |
1 : 30 |
2018-01-01 |
1 : 20 |
2016-11-14 |